DISCOVERED: America is depleting a critical child chemotherapy drug for which it is NOT a suitable substitute because one of its two manufacturers is stopping production.
- for the treatment of all types of childhood cancers
- Vincristine is used in pediatric chemotherapy treatments for diseases such as leukemia, brain tumors and lymphomas
- Pfizer and Teva Pharmaceuticals Industries are the only drug makers delivering Vincristine by 2019
- Teva made a "business decision to discontinue the drug" in July
- An ongoing readmission order has doctors considering giving norms
The recent Vincristine deficiency in the United States has created a "nightmare situation" for US doctors using it to treat any type of childhood cancer
Critical, non-replaceable chemotherapy drug in America is depleting – with doctors warning "nightmare scenario" means they may need to start setting doses
An anti-cancer compound known as Vincristine is a critical component in the treatment of most childhood cancers.
All drug delivery to America comes from only two manufacturers – Pfizer and Teva Pharmaceuticals Industries.
But Teva stopped making Vincristine in July after making a "business decision" to suspend production, according to the US Food and Drug Administration.
Vincristine works by stopping rapidly dividing cancer cells from growing, blocking each of them from assembling their "skeleton" when trying to multiply.
Thousands of children in the United States are diagnosed with cancer each year. In practice, they all rely on Vincristine to combat their illnesses.
The search for the drug created a diary for the drug t
" Pfizer has been delayed and we are working closely with them and are exploring every opportunity to station we believe this critical cancer drug is accessible to patients who need it, "F.D.A. said in a brief statement to the New York Times.
Pfizer spokesman Jessica Smith said in the next few weeks the company would rush in with additional Vincristine shipments to "support our typical production three to four times as often" to try and get the load done
In the current situation, the situation creates a "nightmare" scenario for cancer physicians, who are now forced to consider difficult choices that are likely to affect underage patients.
Vincristine is used in pediatric chemotherapy treatments. It works by stopping rapidly dividing cancer cells from growing, blocking each of them from assembling its "skeleton" when it tries to multiply.  The search for a drug created a diary for the medicine Pfizer struggles to fill ” class=”blkBorder img-share” />
The search for a drug created a diary for the drug that Pfizer struggles to fill
"It's really a nightmare," he told the New York Times Dr. Yoram Unguru, pediatric oncologist at the pediatric hospital Herman and Walter Samuelson Hospital in Sinai, Baltimore.
"Vincristine is our water. This is our bread and butter. I can't think of a childhood cancer disease that doesn't use Vincristine," she added. "There is no substitute for Vincristine that can be recommended. Or should miss a dose or give a lower dose – or beg, borrow or pray. "
Vincristine is just the latest drug from which doctors are experiencing" critical shortage, "according to Forbes.
Eight of the 10 drugs commonly used to treat acute lymphoblastic leukemia – the most common the common childhood cancer, accounting for almost 25 percent of all adolescent forms of the disease, has been inaccessible sometimes for the past 10 years. warns of a "health crisis" caused by a shortage of drugs for several years.
"The government must take a stand. They're already doing it with companies that guarantee water, electricity – why not these basic drugs? "Unguru told the cancer therapist." These drugs are really part of our critical infrastructure and we should treat them as such …
"It's hard enough for any family who has a child with cancer," he said Unguru told the New York Times, "and having a child with cancer who is likely to be cured except we can't give them medicine is beyond imagination. How can we do this to families?"